4
Changes in Ownership
MoonLake Immunotherapeutics Filed Acc 0001213900-24-014996
Chief Scientific Officer sold 60,000 shares at an average $60.91 ($3,654,800)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Reich Kristian · Chief Scientific Officer
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-02-14 | Sale : show line 1 in the form 10b5-1 | −10,000 | $62.42 | $624,200 | 3,017,483 | I |
| 2024-02-14 | Sale : show line 2 in the form 10b5-1 | −10,000 | $62.43 | $624,300 | 130,071 | D |
| 2024-02-15 | Sale : show line 3 in the form 10b5-1 | −10,000 | $60.17 | $601,700 | 3,007,483 | I |
| 2024-02-15 | Sale : show line 4 in the form 10b5-1 | −10,000 | $60.16 | $601,600 | 120,071 | D |
| 2024-02-16 | Sale : show line 5 in the form 10b5-1 | −10,000 | $60.15 | $601,500 | 2,997,483 | I |
| 2024-02-16 | Sale : show line 6 in the form 10b5-1 | −10,000 | $60.15 | $601,500 | 110,071 | D |
| Open-market sales · 60,000 sh · avg $60.91 · $3,654,800 | ||||||
Loading xslF345X05/ownership.xml…